Nilvadipine antagonizes both Aβ vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice

Brain Research

Volumn 999, Issue 1, 2004, Pages 53-61

  Paris, Daniel ^a   Quadros, Amita ^a   Humphrey, James ^a   Patel, Nikunj ^a   Crescentini, Robert ^a   Crawford, Fiona ^a   Mullan, Michael ^a  

^a ROSKAMP INSTITUTE   (United States)

Author keywords

Abeta; Alzheimer; Amyloid; Cerebral blood flow; Nilvadipine; Transgenic

Indexed keywords

AMINO ACID; AMYLOID PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; NILVADIPINE; AMYLOID BETA PROTEIN; DRUG DERIVATIVE; NIFEDIPINE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTERY CONSTRICTION; ARTICLE; BRAIN BLOOD FLOW; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN TISSUE; ISOLATED ARTERY; LASER DOPPLER FLOWMETRY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENIC MOUSE; AGED; ALZHEIMER DISEASE; ANIMAL; AORTA; BRAIN ARTERY; BRAIN CIRCULATION; CEREBROVASCULAR DISEASE; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; MALE; METABOLISM; MIDDLE CEREBRAL ARTERY; ORGAN CULTURE TECHNIQUE; PATHOPHYSIOLOGY; PHYSIOLOGY; VASOCONSTRICTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; AORTA; CALCIUM CHANNEL BLOCKERS; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, TRANSGENIC; MIDDLE CEREBRAL ARTERY; NIFEDIPINE; ORGAN CULTURE TECHNIQUES; RATS; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 1642472817     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.11.061     Document Type: Article

References (39)

1. Bartenstein P., Minoshima S., Hirsch C., Buch K., Willoch F., Mosch D., Schad D., Schwaiger M., Kurz A. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. J. Nucl. Med. 38:1997;1095-1101.
2. Belayev L., Pinard E., Nallet H., Seylaz J., Liu Y., Riyamongkol P., Zhao W., Busto R., Ginsberg M.D. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke. 33:2002;1077-1084.
3. Birkenhager W.H., Forette F., Seux M.L., Wang J.G., Staessen J.A. Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch. Intern. Med. 161:2001;152-156.
4. De Jong G.I., Farkas E., Stienstra C.M., Plass J.R., Keijser J.N., de la Torre J.C., Luiten P.G. Cerebral hypoperfusion yields capillary damage in the hippocampal CA1 area that correlates with spatial memory impairment. Neuroscience. 91:1999;203-210.
5. de la Torre J.C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke. 33:2002;1152-1162.
6. Ellis R.J., Olichney J.M., Thal L.J., Mirra S.S., Morris J.C., Beekly D., Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology. 46:1996;1592-1596.
7. Esiri M.M., Nagy Z., Smith M.Z., Barnetson L., Smith A.D. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet. 354:1999;919-920.
8. Farkas E., Luiten P.G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64:2001;575-611.
9. Forette F., Seux M.L., Staessen J.A., Thijs L., Babarskiene M.R., Babeanu S., Bossini A., Fagard R., Gil-Extremera B., Laks T., Kobalava Z., Sarti C., Tuomilehto J., Vanhanen H., Webster J., Yodfat Y., Birkenhager W.H. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162:2002;2046-2052.
10. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
11. Iadecola C., Zhang F., Niwa K., Eckman C., Turner S.K., Fischer E., Younkin S., Borchelt D.R., Hsiao K.K., Carlson G.A. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2:1999;157-161.
12. Johnson K.A., Albert M.S. Perfusion abnormalities in prodromal AD. Neurobiol. Aging. 21:2000;289-292.
13. Johnson K., Mueller S., Walshe T., English R., Holman B. Cerebral perfusion imaging in Alzheimer's disease. Arch. Neurol. 44:1987;165-168.
14. Kalaria R.N. Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc. Dis. 13:2002;48-52.
15. Kudo T., Imaizumi K., Tanimukai H., Katayama T., Sato N., Nakamura Y., Tanaka T., Kashiwagi Y., Jinno Y., Tohyama M., Takeda M. Are cerebrovascular factors involved in Alzheimer's disease? Neurobiol. Aging. 21:2000;215-224.
16. Launer L.J., Ross G.W., Petrovitch H., Masaki K., Foley D., White L.R., Havlik R.J. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging. 21:2000;49-55.
17. Maxwell C.J., Hogan D.B., Ebly E.M. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian study of health and aging. CMAJ, Can. Med. Assoc. J. 161:1999;501-506.
18. Nagata K., Kondoh Y., Atchison R., Sato M., Satoh Y., Watahiki Y., Hirata Y., Yokoyama E. Vascular and metabolic reserve in Alzheimer's disease. Neurobiol. Aging. 21:2002;301-307.
19. Nagy Z., Esiri M.M., Jobst K.A., Morris J.H., King E.M., McDonald B., Joachim C., Litchfield S., Barnetson L., Smith A.D. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J. Neuropathol. Exp. Neurol. 56:1997;165-170.
20. Naidu A., Quon D., Cordell B. Beta-amyloid peptide produced in vitro is degraded by proteinases released by cultured cells. J. Biol. Chem. 270:1995;1369-1374.
21. Niwa K., Porter V.A., Kazama K., Cornfield D., Carlson G.A., Iadecola C. Abeta-peptides enhance vasoconstriction in cerebral circulation. Am. J. Physiol, Heart Circ. Physiol. 281:2001;H2417-H2424.
22. Niwa K., Kazama K., Younkin S.G., Carlson G.A., Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9:2002;61-68.
23. Ogasawara K., Noda A., Yasuda S., Kobayashi M., Yukawa H., Ogawa A. Effect of calcium antagonist on cerebral blood flow and oxygen metabolism in patients with hypertension and chronic major cerebral artery occlusion: a positron emission tomography study. Nucl. Med. Common. 24:2003;71-76.
24. Paris D., Town T., Mori T., Parker T.A., Humphrey J., Mullan M. Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol. Aging. 21:2000;183-197.
25. Richards S.S., Emsley C.L., Roberts J., Murray M.D., Hall K., Gao S., Hendrie H.C. The association between vascular risk factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans. J. Am. Geriatr. Soc. 48:2000;1035-1041.
26. Rigaud A.S., Seux M.L., Staessen J.A., Birkenhager W.H., Forette F. Cerebral complications of hypertension. J. Hum. Hypertens. 14:2000;605-616.
27. Rigaud A.S., Olde-Rikkert M., Hanon O., Seux M.L., Forette F. Antihypertensive drugs and cognitive function. Curr. Hypertens. Rep. 4:2002;211-215.
28. Scremin O.U., Holschneider D.P., Chen K., Li M.G., Shih J.C. Cerebral cortical blood flow maps are reorganized in MAOB-deficient mice. Brain Res. 824:1999;36-44.
29. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2001;741-766.
30. Shih W.J., Ashford J.W., Coupal J.J., Ryo Y.U., Stipp V.V., Magoun S.L., Gross K. Consecutive brain SPECT surface three-dimensional displays show progression of cerebral cortical abnormalities in Alzheimer's disease. Clin. Nucl. Med. 24:1999;773-777.
31. Shimamoto H., Shimamoto Y. Nilvadipine increases cerebral blood flow in elderly hypertensives: comparison with nifedipine. J. Hum. Hypertens. 9:1995;271-279.
32. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 277:1997;813-817.
33. Staessen J.A., Wang J.G., Thijs L. Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am. J. Hypertens. 15:2002;85S-93S.
34. Steiner H., Capell A., Leimer U., Haass C. Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 249:1999;266-270.
35. Suo Z., Humphrey J., Kundtz A., Sethi F., Placzek A., Crawford F., Mullan M. Soluble Alzheimers beta-amyloid constricts the cerebral vasculature in vivo. Neurosci. Lett. 257:1998;77-80.
36. Suter O.C., Sunthorn T., Kraftsik R., Straubel J., Darekar P., Khalili K., Miklossy J. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke. 33:2002;1986-1992.
37. Takakura S., Satoh Y., Sato H., Mori J., Kohsaka M. Effects of nilvadipine on regional cerebral blood flow and skin blood flow in anesthetized cats. Arch. Int. Pharmacodyn. Ther. 319:1992;38-48.
38. Tokuma Y., Sekiguchi M., Niwa T., Noguchi H. Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. Xenobiotica. 18:1988;21-28.
39. Waldemar G., Bruhn P., Kristensen M., Johnsen A., Paulson O.B., Lassen N.A. Heterogeneity of neocortical cerebral blood flow deficits in dementia of the Alzheimer type: a [99mTc]-d,1-HMPAO SPECT study. J. Neurol. Neurosurg. Psychiatry. 57:1994;285-295.